Drug Patents Expiring in 2033
1. Abilify Asimtufii patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10517951 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
| US11638757 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
| US11097007 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 27 April, 2023
Treatment: Maintenance monotherapy treatment of bipolar i disorder
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY ASIMTUFII family patents
2. Abilify Maintena Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11400087 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US11344547 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US11154553 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US10980803 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-746) | Jul 27, 2020 |
| New Dosage Form(NDF) | Feb 28, 2016 |
| M(M-150) | Dec 05, 2017 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Treatment of schizophrenia; Maintenance monotherapy treatment of bipolar i disorder
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY MAINTENA KIT family patents
3. Abilify Mycite Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9577864 | OTSUKA | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
Oct, 2033
(9 years from now) | |
| US9268909 | OTSUKA | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient; Method of using a logic circuit to stabilize battery v...
Dosage: TABLET;ORAL
ABILIFY MYCITE KIT family patents
4. Aczone patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273132 | ALMIRALL | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Nov, 2033
(9 years from now) | |
| US9517219 | ALMIRALL | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Nov, 2033
(9 years from now) | |
| US9161926 | ALMIRALL | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Feb 24, 2019 |
| New Patient Population(NPP) | Sep 10, 2022 |
Drugs and Companies using DAPSONE ingredient
Market Authorisation Date: 24 February, 2016
Treatment: Topical treatment of acne vulgaris
Dosage: GEL;TOPICAL
ACZONE family patents
5. Admelog Solostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717852 | SANOFI-AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2020 |
Drugs and Companies using INSULIN LISPRO ingredient
Market Authorisation Date: 11 December, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
ADMELOG SOLOSTAR family patents
6. Aklief patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9498465 | GALDERMA LABS LP | Topical compositions in the form of a gel containing a particular solubilized retinoid |
May, 2033
(9 years from now) | |
| US9084778 | GALDERMA LABS LP | Topical compositions containing a retinoid of the oil-in-water emulsion type |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 04, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: 05 October, 2023
Market Authorisation Date: 04 October, 2019
Treatment: Topical treatment of acne vulgaris; Treatment of acne vulgaris
Dosage: CREAM;TOPICAL
AKLIEF family patents
7. Alkindi Sprinkle patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675559 | ETON | Treatment of adrenal insufficiency |
Jan, 2033
(8 years from now) | |
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 29 September, 2020
Treatment: Treatment of adrenal insufficiency
Dosage: GRANULE;ORAL
ALKINDI SPRINKLE family patents
8. Antara (micronized) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9314447 | LUPIN | Reduced dose pharmaceutical compositions of fenofibrate |
May, 2033
(9 years from now) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 18 October, 2013
Treatment: Treating severe hypertriglyceridemia
Dosage: CAPSULE;ORAL
ANTARA (MICRONIZED) family patents
9. Apidra Solostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717852 | SANOFI AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
APIDRA SOLOSTAR family patents
10. Aristada patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9193685 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(9 years from now) | |
| US11097006 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA family patents
11. Arymo Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549899 | ZYLA | Abuse deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(9 years from now) | |
| US9044402 | ZYLA | Abuse-deterrent pharmaceutical compositions for controlled release |
Jul, 2033
(9 years from now) | |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 09 January, 2017
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE;ORAL
ARYMO ER family patents
12. Austedo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9550780 | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11666566 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US9296739 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US9233959 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| US9814708 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
| M(M-54) | Jun 24, 2024 |
| Pediatric Exclusivity(PED) | Dec 24, 2024 |
| New Indication(I-751) | Aug 30, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Treatment: A method of treating huntington's chorea
Dosage: TABLET;ORAL
AUSTEDO family patents
13. Austedo Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9550780 | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(9 years from now) | |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: A method of treating huntington's chorea
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUSTEDO XR family patents
14. Auvelity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8569328 | AXSOME | Compositions and methods comprising tilidine or related compounds and dextromethorphan |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUVELITY family patents
15. Balversa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8895601 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2024 |
| New Indication(I-930) | Jan 19, 2027 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: 13 April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: NA
Dosage: TABLET;ORAL
BALVERSA family patents
16. Baxdela patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
| New Indication(I-815) | Oct 24, 2022 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
BAXDELA family patents
17. Belsomra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098892 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-253) | Jan 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2019 |
Drugs and Companies using SUVOREXANT ingredient
NCE-1 date: 13 August, 2018
Market Authorisation Date: 13 August, 2014
Treatment: NA
Dosage: TABLET;ORAL
BELSOMRA family patents
18. Belviq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8999970 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 27 June, 2012
Treatment: Method for chronic weight management by decreasing food intake in an individual who does not have severe renal impairment or esrd
Dosage: TABLET;ORAL
BELVIQ family patents
19. Belviq Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8999970 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 15 July, 2016
Treatment: Method for chronic weight management by treating obesity in an individual who does not have severe renal impairment or esrd
Dosage: TABLET, EXTENDED RELEASE;ORAL
BELVIQ XR family patents
20. Bendeka patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9597397 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9572887 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9579384 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(8 years from now) | |
| US9597399 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9144568 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9034908 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9000021 | EAGLE PHARMS | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Mar, 2033
(8 years from now) | |
| US10052385 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| US9597398 | EAGLE PHARMS | Formulations of bendamustine |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-179) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2015
Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For use in the treatment of patients with chronic lymphocytic ...
Dosage: SOLUTION;IV (INFUSION)
BENDEKA family patents
21. Biktarvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9216996 | GILEAD SCIENCES INC | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
Dec, 2033
(9 years from now) | |
| US9732092 | GILEAD SCIENCES INC | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections |
Dec, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-256) | Jun 18, 2026 |
| M(M-82) | Feb 24, 2024 |
| Orphan Drug Exclusivity(ODE-468) | Feb 23, 2031 |
| Orphan Drug Exclusivity(ODE-378) | Oct 07, 2028 |
| New Chemical Entity Exclusivity(NCE) | Feb 07, 2023 |
| New Patient Population(NPP) | Jun 18, 2022 |
NCE-1 date: 07 February, 2022
Market Authorisation Date: 07 October, 2021
Treatment: NA
Dosage: TABLET;ORAL
BIKTARVY family patents
22. Bonjesta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9937132 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(8 years from now) | |
| US9089489 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(8 years from now) | |
| US9526703 | DUCHESNAY | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(8 years from now) | |
| US9375404 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(8 years from now) | |
Drugs and Companies using DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 November, 2016
Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management
Dosage: TABLET, EXTENDED RELEASE;ORAL
BONJESTA family patents
23. Braftovi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474754 | ARRAY BIOPHARMA INC | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
| Orphan Drug Exclusivity(ODE-445) | Oct 11, 2030 |
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
| New Indication(I-826) | Apr 08, 2023 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-ap...
Dosage: CAPSULE;ORAL
BRAFTOVI family patents
24. Byfavo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9561236 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Apr, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2025 |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
NCE-1 date: 06 October, 2024
Market Authorisation Date: 06 October, 2020
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER;INTRAVENOUS
BYFAVO family patents
25. Cabometyx patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9724342 | EXELIXIS INC | C-met modulator pharmaceutical compositions |
Jul, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| New Indication(I-854) | Jan 22, 2024 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
| New Indication(I-873) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Indication(I-760) | Dec 19, 2020 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-792) | Jan 14, 2022 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: NA
Dosage: TABLET;ORAL
CABOMETYX family patents
26. Caplyta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48839 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
| New Indication(I-882) | Dec 17, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: Treatment of bipolar depression
Dosage: CAPSULE;ORAL
CAPLYTA family patents
27. Carnexiv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | LUNDBECK PHARMS LLC | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 07, 2023 |
| Orphan Drug Exclusivity(ODE-124) | Oct 07, 2023 |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 07 October, 2016
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
CARNEXIV family patents
28. Cequa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10441630 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(9 years from now) | |
| US8980839 | SUN PHARM | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof |
Aug, 2033
(9 years from now) | |
| US9937225 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(9 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 14 August, 2018
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: SOLUTION;OPHTHALMIC
CEQUA family patents
29. Clorotekal patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504666 | B BRAUN MEDICAL INC | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 26, 2020 |
Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 September, 2017
Treatment: NA
Dosage: SOLUTION;INTRATHECAL
CLOROTEKAL family patents
30. Complera patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857102 | GILEAD SCIENCES INC | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 13, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
NCE-1 date: 21 May, 2015
Market Authorisation Date: 10 August, 2011
Treatment: NA
Dosage: TABLET;ORAL
COMPLERA family patents
31. Contrave patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10403170 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(9 years from now) | |
| US11139056 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(9 years from now) | |
| US9633575 | NALPROPION | Methods of treating overweight and obesity |
Jun, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE;ORAL
CONTRAVE family patents
32. Cytalux patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9061057 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9333270 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9341629 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US10881747 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9789208 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9254341 | ON TARGET LABS | Methods of manufacture of pteroyl-amino acid-fluorescent dyes |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2026 |
| New Indication(I-905) | Dec 16, 2025 |
| Orphan Drug Exclusivity(ODE-390) | Nov 29, 2028 |
Drugs and Companies using PAFOLACIANINE SODIUM ingredient
NCE-1 date: 29 November, 2025
Market Authorisation Date: 29 November, 2021
Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions
Dosage: SOLUTION;INTRAVENOUS
CYTALUX family patents
33. Daptomycin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357535 | HOSPIRA | Daptomycin formulations and uses thereof |
Sep, 2033
(9 years from now) | |
| US9655946 | HOSPIRA | Daptomycin formulations and uses thereof |
Sep, 2033
(9 years from now) | |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 21 June, 2021
Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administerin...
Dosage: POWDER;INTRAVENOUS
DAPTOMYCIN family patents
34. Descovy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-285) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-284) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-457) | Jan 07, 2029 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Patient Population(NPP) | Sep 28, 2020 |
| New Indication(I-812) | Oct 03, 2022 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 07 January, 2022
Treatment: NA
Dosage: TABLET;ORAL
DESCOVY family patents
35. Docetaxel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9308195 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
| US8940786 | SHILPA | Non-aqueous taxane nanodispersion formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
| US9763880 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
Drugs and Companies using DOCETAXEL ingredient
Market Authorisation Date: 22 December, 2015
Treatment: Method of administering an ethanol-free taxane liquid nanodispersion formulation to a subject combining the formulation with an aqueous medium to provide an ethanol-free taxane diluted solution; Treat...
Dosage: INJECTABLE;INJECTION
DOCETAXEL family patents
36. Empaveli patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(8 years from now) | |
| US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(9 years from now) | |
| US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
| Orphan Drug Exclusivity(ODE-351) | May 14, 2028 |
| M(M-288) | Feb 08, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 14 May, 2021
Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administrat...
Dosage: SOLUTION;SUBCUTANEOUS
EMPAVELI family patents
37. Entresto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9517226 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(9 years from now) | |
| US9937143 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(9 years from now) | |
| US11135192 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-82) | Feb 16, 2024 |
| Pediatric Exclusivity(PED) | Apr 01, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2020 |
| New Patient Population(NPP) | Oct 01, 2022 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
NCE-1 date: 01 April, 2022
Market Authorisation Date: 07 July, 2015
Treatment: Treatment of heart failure with preserved ejection fraction
Dosage: TABLET;ORAL
ENTRESTO family patents
38. Epanova patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9050309 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9050308 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
| US10117844 | ASTRAZENECA | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 05, 2019 |
Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient
NCE-1 date: 05 May, 2018
Market Authorisation Date: 05 May, 2014
Treatment: Treatment of hypertriglyceridemia; Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet
Dosage: CAPSULE;ORAL
EPANOVA family patents
39. Epclusa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
| M(M-264) | Jul 14, 2023 |
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
| M(M-277) | Apr 27, 2025 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| New Patient Population(NPP) | Mar 19, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
| New Strength(NS) | Mar 19, 2023 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 19 March, 2020
Treatment: NA
Dosage: TABLET;ORAL; PELLETS;ORAL
EPCLUSA family patents
40. Erleada patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9481663 | JANSSEN BIOTECH | Crystalline forms of an androgen receptor modulator |
Jun, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10849888 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
| US9884054 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
| USRE49353 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
| US10052314 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-808) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 14 February, 2018
Treatment: Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in co...
Dosage: TABLET;ORAL
ERLEADA family patents
41. Esbriet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778947 | GENENTECH INC | Methods of administering pirfenidone therapy |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 11 January, 2017
Treatment: Administration of pirfenidone and avoiding concurrent administration of ciprofloxacin at a dose of 750 mg to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder
Dosage: CAPSULE;ORAL; TABLET;ORAL
ESBRIET family patents
42. Esmolol Hydrochloride Double Strength In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835505 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) | |
| US8829054 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) | |
Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 07 April, 2016
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER family patents
43. Esmolol Hydrochloride In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835505 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) | |
| US8829054 | HQ SPCLT PHARMA | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
Mar, 2033
(8 years from now) | |
Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 07 April, 2016
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER family patents
44. Evomela patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | ACROTECH BIOPHARMA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Mar 10, 2023 |
| Orphan Drug Exclusivity(ODE-110) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
EVOMELA family patents
45. Evrysdi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-334) | Aug 07, 2027 |
| New Chemical Entity Exclusivity(NCE) | Aug 07, 2025 |
| Orphan Drug Exclusivity(ODE-400) | May 27, 2029 |
| New Patient Population(NPP) | May 27, 2025 |
| M(M-270) | Oct 03, 2026 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 07 August, 2024
Market Authorisation Date: 07 August, 2020
Treatment: NA
Dosage: FOR SOLUTION;ORAL
EVRYSDI family patents
46. Eysuvis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11219596 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9737491 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9393213 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10058511 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9827191 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10688045 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9056057 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US11596599 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10945948 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10940108 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10993908 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9532955 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10646436 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10857096 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 26, 2023 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 26 October, 2020
Treatment: A method for treating dry eye in a patient; A method for delivering a pharmaceutical agent across a mucosal barrier; A method for delivering a composition to a mucus membrane; Administration to the ey...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
EYSUVIS family patents
47. Fetroja patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI INC | Cephalosporin having catechol group |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 14, 2029 |
| New Indication(I-844) | Sep 25, 2023 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 14 November, 2028
Market Authorisation Date: 14 November, 2019
Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate
Dosage: POWDER;INTRAVENOUS
FETROJA family patents
48. Fintepla patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549909 | UCB INC | Method for the treatment of dravet syndrome |
May, 2033
(9 years from now) | |
| US9603815 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
| US10478442 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(9 years from now) | |
| US10478441 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
| US9610260 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(9 years from now) | |
| US9603814 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(9 years from now) | |
|
US9549909 (Pediatric) | UCB INC | Method for the treatment of dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US9610260 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(9 years from now) | |
|
US9603814 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US10478442 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(9 years from now) | |
|
US10478441 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
|
US9603815 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-312) | Jun 25, 2027 |
| New Indication(I-887) | Mar 25, 2025 |
| Orphan Drug Exclusivity(ODE-393) | Mar 25, 2029 |
| New Product(NP) | Jun 25, 2023 |
| Pediatric Exclusivity(PED) | Sep 25, 2029 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated...
Dosage: SOLUTION;ORAL
FINTEPLA family patents
49. Genvoya patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: NA
Dosage: TABLET;ORAL
GENVOYA family patents
50. Givlaari patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10125364 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(8 years from now) | |
| US9133461 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Nov, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9631193 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS
GIVLAARI family patents
51. Harvoni patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9393256 (Pediatric) | GILEAD SCIENCES INC | Methods for treating HCV |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-136) | Apr 07, 2024 |
| ODE*(ODE*) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Dosing Schedule(D-158) | Feb 12, 2019 |
| New Dosing Schedule(D-159) | Feb 12, 2019 |
| New Dosing Schedule(D-160) | Feb 12, 2019 |
| New Patient Population(NPP) | Apr 07, 2020 |
| New Indication(I-718) | Nov 12, 2018 |
| New Dosing Schedule(D-153) | Nov 12, 2018 |
| New Indication(I-719) | Nov 12, 2018 |
| New Indication(I-720) | Nov 12, 2018 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: NA
Dosage: TABLET;ORAL; PELLETS;ORAL
HARVONI family patents
52. Hepzato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10195334 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 14, 2026 |
| Orphan Drug Exclusivity(ODE-438) | Aug 14, 2030 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 August, 2023
Treatment: NA
Dosage: POWDER;INTRA-ARTERIAL
HEPZATO family patents
53. Hetlioz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9855241 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10449176 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9549913 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9060995 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US8785492 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11850229 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11833130 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| USRE46604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11633377 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10945988 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-330) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2021 |
| New Indication(I-850) | Dec 01, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-59) | Jan 31, 2021 |
Drugs and Companies using TASIMELTEON ingredient
NCE-1 date: 31 January, 2018
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists; Treatment of non-24 hour sleep-wake disorder by administering tasi...
Dosage: CAPSULE;ORAL
HETLIOZ family patents
54. Hetlioz Lq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11633377 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11833130 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11850229 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-329) | Dec 01, 2027 |
| New Product(NP) | Dec 01, 2023 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenis syndrome...
Dosage: SUSPENSION;ORAL
HETLIOZ LQ family patents
55. Ibsrela patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Treatment: NA
Dosage: TABLET;ORAL
IBSRELA family patents
56. Iclusig patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11192897 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(9 years from now) | |
| US9493470 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(9 years from now) | |
| US11384086 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11192895 | TAKEDA PHARMS USA | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-934) | Mar 19, 2027 |
| New Indication(I-849) | Dec 18, 2023 |
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE-35) | Dec 14, 2019 |
Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 18 December, 2020
Treatment: A method for treating chronic myeloid leukemia; A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; A method for treating leukemia resulting from a mutation in the bcr...
Dosage: TABLET;ORAL
ICLUSIG family patents
57. Idhifa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512107 | BRISTOL MYERS SQUIBB | Therapeutically active compositions and their methods of use |
Jan, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10294215 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-151) | Aug 01, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 01, 2024 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2022 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: 01 August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL
IDHIFA family patents
58. Imbruvica patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10106548 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(9 years from now) | |
| US10125140 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(9 years from now) | |
| US9725455 | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(9 years from now) | |
| US9296753 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10294232 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(9 years from now) | |
| US9713617 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(9 years from now) | |
| US10961251 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(9 years from now) | |
| US10294231 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(9 years from now) | |
| US10752634 | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(9 years from now) | |
| US9540382 | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(9 years from now) | |
|
US9725455 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10961251 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10752634 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10125140 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10106548 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10294232 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US10294231 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
|
US9713617 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
| New Patient Population(NPP) | Aug 24, 2025 |
| ODE*(ODE*) | Aug 02, 2024 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| M(M-236) | Jan 25, 2022 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| New Indication(I-736) | May 06, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-753) | Aug 02, 2020 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Indication(I-689) | Jul 28, 2017 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| New Indication(I-729) | Mar 04, 2019 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 20 December, 2017
Treatment: Treatment of mantle cell lymphoma
Dosage: CAPSULE;ORAL; TABLET;ORAL; SUSPENSION;ORAL
IMBRUVICA family patents
59. Imvexxy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10471072 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US11065197 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10888516 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10568891 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US11116717 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10668082 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US11123283 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10258630 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(9 years from now) | |
| US9180091 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Dec, 2033
(9 years from now) | |
| US10398708 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2021 |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy; Treatment of moderate to severe dyspareunia
Dosage: INSERT;VAGINAL
IMVEXXY family patents
60. Infugem patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9241948 | SUN PHARM | Ready to be infused gemcetabine solution |
Jul, 2033
(9 years from now) | |
Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 July, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
INFUGEM family patents
61. Inveltys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11219597 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10058511 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10864219 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9056057 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10688045 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9393213 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9737491 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9827191 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10646437 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9532955 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 22, 2021 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 August, 2018
Treatment: A method of treating postoperative inflammation following ocular surgery; A method for delivering a pharmaceutical agent across a mucosal barrier; A method for treating ocular inflammation; A method f...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
INVELTYS family patents
62. Ionsys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9095706 | THE MEDICINES CO | Self-test for analgesic product |
Feb, 2033
(8 years from now) | |
Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 May, 2006
Treatment: NA
Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS family patents
63. Jentadueto Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555001 | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Mar, 2033
(8 years from now) | |
|
US9555001 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin
Dosage: TABLET, EXTENDED RELEASE;ORAL
JENTADUETO XR family patents
64. Kalydeco patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11147770 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US10272046 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US8883206 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US11752106 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
| New Patient Population(NPP) | Apr 29, 2022 |
| New Indication(I-740) | Feb 21, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 01 February, 2016
Market Authorisation Date: 03 May, 2023
Treatment: Treatment of cf in a patient age 1 month to <4 months who has at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition ...
Dosage: GRANULE;ORAL
KALYDECO family patents
65. Kengreal patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8680052 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 22, 2020 |
Drugs and Companies using CANGRELOR ingredient
NCE-1 date: 23 June, 2019
Market Authorisation Date: 22 June, 2015
Treatment: Method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading d...
Dosage: POWDER;INTRAVENOUS
KENGREAL family patents
66. Korlym patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10500216 | CORCEPT THERAP | Optimizing mifepristone absorption |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-22) | Feb 17, 2019 |
| New Product(NP) | Feb 17, 2015 |
| Orphan Drug Exclusivity(ODE) | Feb 17, 2019 |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET;ORAL
KORLYM family patents
67. Kuvan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9216178 (Pediatric) | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
May, 2033
(9 years from now) | |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2013
Treatment: NA
Dosage: POWDER;ORAL
KUVAN family patents
68. Kyprolis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | ONYX PHARMS AMGEN | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-712) | Jul 24, 2018 |
| New Indication(I-722) | Jan 21, 2019 |
| New Indication(I-723) | Jan 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2017 |
| Orphan Drug Exclusivity(ODE) | Jul 20, 2019 |
| New Dosing Schedule(D-172) | Sep 28, 2021 |
| Orphan Drug Exclusivity(ODE-27) | Jul 20, 2019 |
| New Indication(I-842) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
NCE-1 date: 20 July, 2016
Market Authorisation Date: 07 June, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS
KYPROLIS family patents
69. Kyzatrex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11617758 | MARIUS PHARMS LLC | Emulsion formulations |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE;ORAL
KYZATREX family patents
70. Lantus Solostar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717852 | SANOFI AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: INJECTABLE;INJECTION
LANTUS SOLOSTAR family patents
71. Liletta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11090186 | MEDICINES360 | Methods for using intrauterine systems and IUD insertion devices |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-917) | Jun 29, 2026 |
| New Product(NP) | Feb 26, 2018 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 26 February, 2015
Treatment: A method for prevention of pregnancy
Dosage: INTRAUTERINE DEVICE;INTRAUTERINE
LILETTA family patents
72. Linzess patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9708371 | ABBVIE | Treatments for gastrointestinal disorders |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-921) | Jun 12, 2026 |
| New Strength(NS) | Jan 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 30 August, 2012
Treatment: Method of treating chronic idiopathic constipation in adult patients.
Dosage: CAPSULE;ORAL
LINZESS family patents
73. Liposyn Iii 30% patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717852 | HOSPIRA | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
Drugs and Companies using SOYBEAN OIL ingredient
Market Authorisation Date: 13 January, 1998
Treatment: NA
Dosage: INJECTABLE;INJECTION
LIPOSYN III 30% family patents
74. Lokelma patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10695365 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(9 years from now) | |
| US8877255 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(9 years from now) | |
| US9913860 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2023 |
| M(M-261) | Apr 24, 2023 |
Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient
NCE-1 date: 18 May, 2022
Market Authorisation Date: 18 May, 2018
Treatment: Treatment of hyperkalemia in adults
Dosage: FOR SUSPENSION;ORAL
LOKELMA family patents
75. Lonhala Magnair Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9604018 | SUMITOMO PHARMA AM | Aerosol therapy device |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION;INHALATION
LONHALA MAGNAIR KIT family patents
76. Lorbrena patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8680111 | PFIZER | Macrocyclic derivatives for the treatment of diseases |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-218) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-219) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-217) | Nov 02, 2025 |
| Orphan Drug Exclusivity(ODE-349) | Mar 03, 2028 |
| New Indication(I-847) | Mar 03, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 02, 2023 |
Drugs and Companies using LORLATINIB ingredient
NCE-1 date: 02 November, 2022
Market Authorisation Date: 02 November, 2018
Treatment: NA
Dosage: TABLET;ORAL
LORBRENA family patents
77. Luzu patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9199977 | BAUSCH | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
Sep, 2033
(9 years from now) | |
| US9453006 | BAUSCH | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient |
Sep, 2033
(9 years from now) | |
| US9012484 | BAUSCH | Crystal and pharmaceutical preparation containing the same crystal |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2018 |
| New Patient Population(NPP) | Feb 20, 2021 |
Drugs and Companies using LULICONAZOLE ingredient
NCE-1 date: 14 November, 2017
Market Authorisation Date: 14 November, 2013
Treatment: Treatment of fungal infections
Dosage: CREAM;TOPICAL
LUZU family patents
78. Lytgobi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9108973 | TAIHO ONCOLOGY | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2027 |
| Orphan Drug Exclusivity(ODE-410) | Sep 30, 2029 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: 30 September, 2026
Market Authorisation Date: 30 September, 2022
Treatment: Method of treating intrahepatic cholangiocarcinoma
Dosage: TABLET;ORAL
LYTGOBI family patents
79. Mekinist patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| Orphan Drug Exclusivity(ODE-148) | Jun 22, 2024 |
| New Indication(I-908) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
| New Indication(I-895) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Dec 22, 2025 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-48) | May 29, 2020 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE-57) | Jan 08, 2021 |
| New Indication(I-678) | Jan 08, 2017 |
| M(M-246) | Oct 06, 2022 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement o...
Dosage: TABLET;ORAL
MEKINIST family patents
80. Mektovi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9562016 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9980944 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
| US9598376 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
Drugs and Companies using BINIMETINIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Treatment of melanoma with a braf mutation; Method of treating melanoma
Dosage: TABLET;ORAL
MEKTOVI family patents
81. Miebo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10369117 | BAUSCH AND LOMB INC | Compositions comprising mixtures of semifluorinated alkanes |
Sep, 2033
(9 years from now) | |
| US10449164 | BAUSCH AND LOMB INC | Methods of treating ocular disorders using semifluorinated alkanes |
Sep, 2033
(9 years from now) | |
| US10058615 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(9 years from now) | |
| US10576154 | BAUSCH AND LOMB INC | Semifluorinated alkane compositions |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2028 |
Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient
NCE-1 date: 19 May, 2027
Market Authorisation Date: 18 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS;OPHTHALMIC
MIEBO family patents
82. Mitigare patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8927607 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US9399036 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US9789108 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US9555029 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
| US9675613 | HIKMA INTL PHARMS | Methods of colchicine administration |
Aug, 2033
(9 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 26 September, 2014
Treatment: Method of using colchicine for the prophylaxis of gout flares
Dosage: CAPSULE;ORAL
MITIGARE family patents
83. Myfembree patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11795178 | MYOVANT SCIENCES | Compositions of thienopyrimidine derivatives |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
| New Product(NP) | May 26, 2024 |
| M(M-289) | Jan 27, 2026 |
| New Indication(I-898) | Aug 05, 2025 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 26 May, 2021
Treatment: NA
Dosage: TABLET;ORAL
MYFEMBREE family patents
84. Naftin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778365 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10166206 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10166205 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US9161914 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10695303 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10729667 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 27, 2016 |
Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 June, 2013
Treatment: Treatment of fungal infections
Dosage: GEL;TOPICAL
NAFTIN family patents
85. Natroba patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9895388 | PARAPRO LLC | Methods and compositions useful for controlling cutaneous mites |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-858) | Apr 28, 2024 |
| M(M-152) | Nov 30, 2017 |
| New Chemical Entity Exclusivity(NCE) | Jan 18, 2016 |
Drugs and Companies using SPINOSAD ingredient
NCE-1 date: 18 January, 2015
Market Authorisation Date: 18 January, 2011
Treatment: The product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and delivering the active ingredient, spinosad, to the stratum corneum where scabies mites ...
Dosage: SUSPENSION;TOPICAL
NATROBA family patents
86. Noxafil patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 31, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
| New Indication(I-881) | Jun 17, 2024 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
NOXAFIL family patents
87. Nubeqa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8975254 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 30, 2024 |
| New Indication(I-900) | Aug 05, 2025 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: 31 July, 2023
Market Authorisation Date: 30 July, 2019
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET;ORAL
NUBEQA family patents
88. Nurtec Odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8759372 | PFIZER | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 27, 2025 |
| New Indication(I-865) | May 27, 2024 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: 28 February, 2024
Market Authorisation Date: 27 February, 2020
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
NURTEC ODT family patents
89. Ocaliva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10174073 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238673 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(9 years from now) | |
| US10047117 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 27, 2023 |
| Orphan Drug Exclusivity(ODE-119) | May 27, 2023 |
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
Drugs and Companies using OBETICHOLIC ACID ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: Treatment of primary biliary cholangitis (pbc)
Dosage: TABLET;ORAL
OCALIVA family patents
90. Odefsey patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| M(M-207) | Aug 21, 2020 |
| M(M-206) | Aug 21, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 01 March, 2016
Treatment: NA
Dosage: TABLET;ORAL
ODEFSEY family patents
91. Omidria patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9066856 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
| US9486406 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
| US9855246 | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2017 |
| New Patient Population(NPP) | Dec 08, 2020 |
| Pediatric Exclusivity(PED) | Jun 08, 2021 |
Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2014
Treatment: NA
Dosage: SOLUTION;IRRIGATION
OMIDRIA family patents
92. Onivyde patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11369597 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies |
Jun, 2033
(9 years from now) | |
| US9717724 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies |
Jun, 2033
(9 years from now) | |
| US9492442 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
| US9339497 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
| US9452162 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
| US10980795 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
| US9364473 | IPSEN INC | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-463) | Feb 13, 2031 |
| New Indication(I-932) | Feb 13, 2027 |
| Orphan Drug Exclusivity(ODE-99) | Oct 22, 2022 |
| Orphan Drug Exclusivity(ODE) | Oct 22, 2022 |
| New Product(NP) | Oct 22, 2018 |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2015
Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of pancreatic cancer that has prog...
Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS
ONIVYDE family patents
93. Onzetra Xsail patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478574 | CURRAX | Nasal administration |
Nov, 2033
(9 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Method of delivering sumatriptan to a nasal cavity
Dosage: POWDER;NASAL
ONZETRA XSAIL family patents
94. Opfolda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278599 | AMICUS THERAP US | High concentration alpha-glucosidase compositions for the treatment of Pompe disease |
Mar, 2033
(8 years from now) | |
| US10512677 | AMICUS THERAP US | High concentration alpha-glucosidase compositions for the treatment of pompe disease |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2026 |
Drugs and Companies using MIGLUSTAT ingredient
Market Authorisation Date: 28 September, 2023
Treatment: The treatment of pompe patients
Dosage: CAPSULE;ORAL
OPFOLDA family patents
95. Orfadin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9301932 | SWEDISH ORPHAN | Liquid pharmaceutical composition comprising nitisinone |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-169) | Sep 01, 2020 |
Drugs and Companies using NITISINONE ingredient
Market Authorisation Date: 22 April, 2016
Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
Dosage: SUSPENSION;ORAL
ORFADIN family patents
96. Orgovyx patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11795178 | SUMITOMO PHARMA | Compositions of thienopyrimidine derivatives |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: NA
Dosage: TABLET;ORAL
ORGOVYX family patents
97. Oxbryta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9018210 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2024 |
| Orphan Drug Exclusivity(ODE-394) | Dec 17, 2028 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: 26 November, 2023
Market Authorisation Date: 17 December, 2021
Treatment: NA
Dosage: TABLET;ORAL
OXBRYTA family patents
98. Ozempic patents expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335462 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof
Dosage: SOLUTION;SUBCUTANEOUS
OZEMPIC family patents
99. Pemazyre patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10131667 | INCYTE CORP | Substituted tricyclic compounds as FGFR inhibitors |
Jun, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| Orphan Drug Exclusivity(ODE-292) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-404) | Aug 26, 2029 |
| New Indication(I-899) | Aug 26, 2025 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement
Dosage: TABLET;ORAL
PEMAZYRE family patents
100. Phenylephrine Hydrochloride patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859623 | PARAGON BIOTECK | Methods and compositions of stable phenylephrine formulations |
Nov, 2033
(9 years from now) | |
Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 March, 2013
Treatment: Dilation of the pupil
Dosage: SOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE family patents
101. Phexxi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11439610 | EVOFEM INC | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
Mar, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10568855 | EVOFEM INC | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
Mar, 2033
(8 years from now) | |
| US11337989 | EVOFEM INC | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 22, 2023 |
Drugs and Companies using CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE ingredient
Market Authorisation Date: 22 May, 2020
Treatment: Prevention of pregnancy
Dosage: GEL;VAGINAL
PHEXXI family patents
102. Picato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789078 | LEO LABS | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-169) | Nov 19, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2017 |
Drugs and Companies using INGENOL MEBUTATE ingredient
NCE-1 date: 24 January, 2016
Market Authorisation Date: 23 January, 2012
Treatment: Topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate
Dosage: GEL;TOPICAL
PICATO family patents
103. Piqray patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| New Indication(I-937) | Jan 18, 2027 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 24 May, 2019
Treatment: In combination with fulvestrant for treatment of postmenopausal women, and men, with hr-positive, her-2-negative, pik3ca-mutated, advanced or metastatic breast cancer
Dosage: TABLET;ORAL
PIQRAY family patents
104. Plenvu patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9707297 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
| US10016504 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
| US8999313 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
| US10918723 | SALIX | Colon cleansing compositions and methods of use |
Sep, 2033
(9 years from now) | |
| US9326969 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 04, 2021 |
Market Authorisation Date: 04 May, 2018
Treatment: For cleansing of the colon in preparation for colonoscopy in adults
Dosage: FOR SOLUTION;ORAL
PLENVU family patents
105. Prevymis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603384 | MERCK SHARP DOHME | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
| New Indication(I-916) | Jun 05, 2026 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
Drugs and Companies using LETERMOVIR ingredient
NCE-1 date: 08 November, 2021
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
PREVYMIS family patents
106. Prolensa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9517220 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2016 |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery
Dosage: SOLUTION/DROPS;OPHTHALMIC
PROLENSA family patents
107. Pyrukynd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11793806 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-392) | Feb 17, 2029 |
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2027 |
Drugs and Companies using MITAPIVAT SULFATE ingredient
NCE-1 date: 17 February, 2026
Market Authorisation Date: 17 February, 2022
Treatment: Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency
Dosage: TABLET;ORAL
PYRUKYND family patents
108. Qbrexza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10548875 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10004717 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| US10543192 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| US9259414 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| US8859610 | JOURNEY | Crystalline glycopyrrolate tosylate |
Feb, 2033
(8 years from now) | |
| US9006462 | JOURNEY | Glycopyrrolate salts |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2021 |
Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient
Market Authorisation Date: 28 June, 2018
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: CLOTH;TOPICAL
QBREXZA family patents
109. Qelbree patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9662338 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| US9358204 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| US9603853 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2026 |
| New Patient Population(NPP) | Apr 29, 2025 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2025
Market Authorisation Date: 02 April, 2021
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
QELBREE family patents
110. Qudexy Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9101545 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US9555005 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US8652527 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US10363224 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
| US8889190 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(8 years from now) | |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: Treatment of seizures
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
QUDEXY XR family patents
111. Quillichew Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103495 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US9545399 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US9844544 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US11633389 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US9295642 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US8999386 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US10857143 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| US11103494 | NEXTWAVE PHARMS | Methylphenidate extended release chewable tablet |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 04, 2018 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 December, 2015
Treatment: A method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed; A method of providing a subject with ther...
Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL
QUILLICHEW ER family patents
112. Qulipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9850246 | ABBVIE | Process for making CGRP receptor antagonists |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: NA
Dosage: TABLET;ORAL
QULIPTA family patents
113. Quviviq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9732075 | IDORSIA | Benzimidazole-proline derivatives |
Jun, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: 07 April, 2026
Market Authorisation Date: 07 April, 2022
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
QUVIVIQ family patents
114. Relyvrio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9872865 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
| US11071742 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
| US10857162 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
| US10251896 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2027 |
| Orphan Drug Exclusivity(ODE-411) | Sep 29, 2029 |
Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient
NCE-1 date: 29 September, 2026
Market Authorisation Date: 29 September, 2022
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults
Dosage: FOR SUSPENSION;ORAL
RELYVRIO family patents
115. Rezurock patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815820 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(9 years from now) | |
| US10183931 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(9 years from now) | |
| US10696660 | KADMON PHARMS LLC | Rho kinase inhibitors |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2026 |
| Orphan Drug Exclusivity(ODE-362) | Jul 16, 2028 |
Drugs and Companies using BELUMOSUDIL MESYLATE ingredient
NCE-1 date: 16 July, 2025
Market Authorisation Date: 16 July, 2021
Treatment: For the treatment of chronic graft versus hold disease; For the treatment of chronic graft versus host disease
Dosage: TABLET;ORAL
REZUROCK family patents
116. Rezzayo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9526835 | CIDARA THERAPS | Dosing regimens for echinocandin class compounds |
Mar, 2033
(8 years from now) | |
| US10702573 | CIDARA THERAPS | Dosing regimens for echinocandin class compounds |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Generating Antibiotic Incentives Now(GAIN) | Mar 22, 2033 |
| Orphan Drug Exclusivity(ODE-426) | Mar 22, 2030 |
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2028 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 22 March, 2032
Market Authorisation Date: 22 March, 2023
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
Dosage: POWDER;INTRAVENOUS
REZZAYO family patents
117. Roszet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9763885 | ALTHERA PHARMS | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(9 years from now) | |
| US10376470 | ALTHERA PHARMS | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(9 years from now) | |
Drugs and Companies using EZETIMIBE; ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 23 March, 2021
Treatment: Treatment of hyperlipidemia
Dosage: TABLET;ORAL
ROSZET family patents
118. Rozlytrek patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9085565 | GENENTECH INC | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649306 | GENENTECH INC | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-265) | Aug 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 15, 2024 |
| Orphan Drug Exclusivity(ODE-313) | Aug 15, 2026 |
| New Patient Population(NPP) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-448) | Oct 20, 2030 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 16 August, 2023
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of ros1-positive non-small cell lung cancer
Dosage: CAPSULE;ORAL
ROZLYTREK family patents
119. Rybelsus patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10933120 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| US11759503 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| US11759502 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| US11759501 | NOVO | Compositions of GLP-1 peptides and preparation thereof |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 20 September, 2019
Treatment: NA
Dosage: TABLET;ORAL
RYBELSUS family patents
120. Ryzodeg 70/30 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9884094 | NOVO | Method of treating diabetes mellitus |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 25 September, 2015
Treatment: Method of improving glycemic control in patients with diabetes mellitus by administering a mixture of insulin degludec and insulin aspart during or around the time of the largest meal of the day
Dosage: SOLUTION;SUBCUTANEOUS
RYZODEG 70/30 family patents
121. Scemblix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2026 |
| Orphan Drug Exclusivity(ODE-382) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-381) | Oct 29, 2028 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: 29 October, 2025
Market Authorisation Date: 29 October, 2021
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
Dosage: TABLET;ORAL
SCEMBLIX family patents
122. Secuado patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11123305 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US9687474 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US10814002 | HISAMITSU | Patch and method for producing the same |
Jul, 2033
(9 years from now) | |
| US10583121 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US10022445 | HISAMITSU | Patch |
Jul, 2033
(9 years from now) | |
| US11813364 | HISAMITSU | Patch |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 11, 2022 |
Drugs and Companies using ASENAPINE ingredient
Market Authorisation Date: 11 October, 2019
Treatment: Method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch
Dosage: SYSTEM;TRANSDERMAL
SECUADO family patents
123. Sesquient patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9493582 | LUPIN | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
Drugs and Companies using FOSPHENYTOIN SODIUM ingredient
Market Authorisation Date: 05 November, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
SESQUIENT family patents
124. Seysara patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9255068 | ALMIRALL | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 01, 2023 |
Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient
NCE-1 date: 01 October, 2022
Market Authorisation Date: 01 October, 2018
Treatment: A method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sa...
Dosage: TABLET;ORAL
SEYSARA family patents
125. Skyclarys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8993640 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(8 years from now) | |
| US9701709 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-427) | Feb 28, 2030 |
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2028 |
Drugs and Companies using OMAVELOXOLONE ingredient
NCE-1 date: 28 February, 2027
Market Authorisation Date: 28 February, 2023
Treatment: NA
Dosage: CAPSULE;ORAL
SKYCLARYS family patents
126. Soaanz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10154963 | SARFE PHARMS | Controlled-release formulations comprising Torsemide |
Oct, 2033
(9 years from now) | |
Drugs and Companies using TORSEMIDE ingredient
Market Authorisation Date: 14 June, 2021
Treatment: NA
Dosage: TABLET;ORAL
SOAANZ family patents
127. Soliqua 100/33 patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9717852 | SANOFI-AVENTIS US | Cartridge holder and pen-type injector |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
SOLIQUA 100/33 family patents
128. Sotyktu patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47929 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
Nov, 2033
(9 years from now) | |
| US10000480 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11021475 | BRISTOL | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 09, 2027 |
Drugs and Companies using DEUCRAVACITINIB ingredient
NCE-1 date: 09 September, 2026
Market Authorisation Date: 09 September, 2022
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Dosage: TABLET;ORAL
SOTYKTU family patents
129. Spravato patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785500 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE*(NCE*) | Mar 05, 2024 |
| New Indication(I-840) | Jul 31, 2023 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant
Dosage: SPRAY;NASAL
SPRAVATO family patents
130. Stribild patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-704) | Dec 17, 2017 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Patient Population(NPP) | Jan 27, 2020 |
| New Product(NP) | Aug 27, 2015 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: NA
Dosage: TABLET;ORAL
STRIBILD family patents
131. Syfovre patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(8 years from now) | |
| US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(9 years from now) | |
| US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan
Dosage: SOLUTION;INTRAVITREAL
SYFOVRE family patents
132. Symdeko (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(9 years from now) | |
| US10058546 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof |
Jul, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-173) | Feb 12, 2025 |
| Orphan Drug Exclusivity(ODE-247) | Jun 21, 2026 |
| Orphan Drug Exclusivity(ODE-335) | Dec 21, 2027 |
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2023 |
| New Patient Population(NPP) | Jun 21, 2022 |
Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient
NCE-1 date: 12 February, 2022
Market Authorisation Date: 21 June, 2019
Treatment: Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the f508del mutation or heterozygous for the f508del mutation and a second mutation that is responsive ...
Dosage: TABLET;ORAL
SYMDEKO (COPACKAGED) family patents
133. Symproic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10952968 | BDSI | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: 23 March, 2021
Market Authorisation Date: 23 March, 2017
Treatment: NA
Dosage: TABLET;ORAL
SYMPROIC family patents
134. Tafinlar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869869 | NOVARTIS | Method of adjuvant cancer treatment |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| Orphan Drug Exclusivity(ODE-147) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
| New Indication(I-908) | Mar 16, 2026 |
| New Indication(I-894) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Dec 22, 2025 |
| New Indication(I-745) | Jun 22, 2020 |
| New Indication(I-678) | Jan 08, 2017 |
| M(M-170) | Nov 20, 2018 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-47) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-58) | Jan 09, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement o...
Dosage: CAPSULE;ORAL
TAFINLAR family patents
135. Tazverik patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10821113 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
| US9394283 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10245269 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
| US11491163 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
| US9872862 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
| Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
| Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
| New Indication(I-835) | Jun 18, 2023 |
| New Indication(I-836) | Jun 18, 2023 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating relapsed or refractory follicular lymphoma by inhibiting ezh2; Method of treating sarcoma; Method of treating a lung metastasis of epithelioid sarcoma; Method of treating relapsed o...
Dosage: TABLET;ORAL
TAZVERIK family patents
136. Tibsovo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9850277 | SERVIER | Therapeutically active compositions and their methods of use |
Jan, 2033
(8 years from now) | |
| US9474779 | SERVIER | Therapeutically active compositions and their methods of use |
Aug, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10717764 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(8 years from now) | |
| US11667673 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
| Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
| New Indication(I-875) | Aug 25, 2024 |
| New Indication(I-924) | Oct 24, 2026 |
| Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
| Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
| New Indication(I-893) | May 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
| New Indication(I-816) | May 02, 2022 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by an idh1 mutation; A method of treating a cancer characterized by an idh1 mutation wherein th...
Dosage: TABLET;ORAL
TIBSOVO family patents
137. Tigecycline patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855335 | AMNEAL | Tigecycline composition for injection |
Apr, 2033
(8 years from now) | |
| US9855355 | AMNEAL | Method and device for plasma-treating hollow bodies |
Apr, 2033
(8 years from now) | |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 02 August, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS
TIGECYCLINE family patents
138. Tolsura patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10806792 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US10463740 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US9713642 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US9272046 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US8921374 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 11 December, 2018
Treatment: Treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis
Dosage: CAPSULE;ORAL
TOLSURA family patents
139. Trikafta (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11147770 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US8883206 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US11752106 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US10272046 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(8 years from now) | |
| US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 26 April, 2023
Treatment: Treatment of cf in patients aged 2 to <6 years who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data comprising administering a composition ac...
Dosage: GRANULES;ORAL; TABLET;ORAL
TRIKAFTA (COPACKAGED) family patents
140. Trudhesa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940278 | IMPEL PHARMS | Nozzles for nasal drug delivery |
Jan, 2033
(8 years from now) | |
| US9919117 | IMPEL PHARMS | Nozzles for nasal drug delivery |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 02, 2024 |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 02 September, 2021
Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
TRUDHESA family patents
141. Truqap patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9487525 | ASTRAZENECA | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide |
Apr, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039766 | ASTRAZENECA | Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2028 |
Drugs and Companies using CAPIVASERTIB ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2023
Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...
Dosage: TABLET;ORAL
TRUQAP family patents
142. Tukysa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11504370 | SEAGEN | Treatment of brain cancer |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-906) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET;ORAL
TUKYSA family patents
143. Turalio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7893075 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity and uses therefor |
May, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358235 | DAIICHI SANKYO INC | Kinase modulation, and indications therefor |
Jun, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-250) | Aug 02, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2026 |
Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 August, 2023
Market Authorisation Date: 14 October, 2022
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Dosage: CAPSULE;ORAL
TURALIO family patents
144. Tybost patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-260) | Aug 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
| New Patient Population(NPP) | Aug 22, 2022 |
Drugs and Companies using COBICISTAT ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 24 September, 2014
Treatment: NA
Dosage: TABLET;ORAL
TYBOST family patents
145. Ubrelvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8912210 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: NA
Dosage: TABLET;ORAL
UBRELVY family patents
146. Ukoniq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9150579 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US10570142 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10072013 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US9669033 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| US10981919 | TG THERAPS | Selective PI3K delta inhibitors |
Jul, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 05, 2026 |
| Orphan Drug Exclusivity(ODE-343) | Feb 05, 2028 |
| Orphan Drug Exclusivity(ODE-344) | Feb 05, 2028 |
Drugs and Companies using UMBRALISIB TOSYLATE ingredient
NCE-1 date: 05 February, 2025
Market Authorisation Date: 05 February, 2021
Treatment: Relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one pri...
Dosage: TABLET;ORAL
UKONIQ family patents
147. Ultravate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962028 | SUN PHARM INDUSTRIES | Topical steroid composition and method |
Jun, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 06, 2018 |
| New Patient Population(NPP) | Aug 31, 2023 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 06 November, 2015
Treatment: Use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis
Dosage: LOTION;TOPICAL
ULTRAVATE family patents
148. Uzedy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9023897 | TEVA | Biodegradable drug delivery compositions |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 28, 2026 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
UZEDY family patents
149. Vanflyta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675549 | DAIICHI SANKYO INC | Tablet containing composite with cyclodextrin |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Treatment: NA
Dosage: TABLET;ORAL
VANFLYTA family patents
150. Vascepa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10383840 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(9 years from now) | |
| US9693986 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(9 years from now) | |
| US11369582 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(9 years from now) | |
| US10576054 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(9 years from now) | |
| US10278935 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(9 years from now) | |
| US10278937 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(9 years from now) | |
| US9623001 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(9 years from now) | |
| US10668042 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(9 years from now) | |
| US10568861 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(9 years from now) | |
| US10786478 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(9 years from now) | |
| US10792270 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(9 years from now) | |
| US10894028 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(9 years from now) | |
| US11116742 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(9 years from now) | |
| US10278936 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(9 years from now) | |
| US11000499 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(9 years from now) | |
| US10555924 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(9 years from now) | |
| US10555925 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
Jun, 2033
(9 years from now) | |
| US9603826 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(9 years from now) | |
| US9610272 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(9 years from now) | |
| US9918954 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(9 years from now) | |
| US9693985 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(9 years from now) | |
| US9693984 | AMARIN PHARMS | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
Jun, 2033
(9 years from now) | |
| US11298333 | AMARIN PHARMS | Methods of reducing the risk of cardiovascular events in a subject |
Jun, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 26, 2017 |
| New Indication(I-819) | Dec 13, 2022 |
| New Product(NP) | Jul 26, 2015 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
NCE-1 date: 26 July, 2016
Market Authorisation Date: 26 July, 2012
Treatment: Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event in an adult patient with elevated triglyceride levels and at least one risk factor for cardiovascular diseas...
Dosage: CAPSULE;ORAL
VASCEPA family patents
151. Veltassa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9925212 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) | |
| US11123363 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) | |
| US9492476 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 02, 2026 |
| New Strength(NS) | Oct 02, 2026 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Treatment: Treatment of hyperkalemia
Dosage: POWDER;ORAL
VELTASSA family patents
152. Vemlidy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
|
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 17, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| M(M-255) | Feb 04, 2023 |
| M(M-266) | Aug 22, 2023 |
| New Product(NP) | Nov 11, 2019 |
Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 10 November, 2016
Treatment: NA
Dosage: TABLET;ORAL
VEMLIDY family patents
153. Venclexta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11413282 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US11590128 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US10993942 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US11110087 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US9539251 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
| Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
| Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
| Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
| New Indication(I-789) | Nov 21, 2021 |
| New Indication(I-795) | May 15, 2022 |
| M(M-265) | Oct 16, 2023 |
| Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
| M(M-228) | Jun 08, 2021 |
| New Indication(I-782) | Jun 08, 2021 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of adults with relapsed, refractory or previously untreated chronic lymphocytic leukemia including a dose ramp-up and in combination with obinutuzumab in multiple 28-day dosing cycles follow...
Dosage: TABLET;ORAL
VENCLEXTA family patents
154. Viberzi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188632 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11090291 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US9675587 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11484527 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11007179 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11229627 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11311516 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11160792 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2020 |
Drugs and Companies using ELUXADOLINE ingredient
NCE-1 date: 28 May, 2019
Market Authorisation Date: 27 May, 2015
Treatment: Reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-d) patient, with eluxadoline twice daily with food
Dosage: TABLET;ORAL
VIBERZI family patents
155. Victoza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9265893 (Pediatric) | NOVO NORDISK INC | Injection button |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-176) | Apr 22, 2019 |
| New Patient Population(NPP) | Jun 17, 2022 |
| New Indication(I-750) | Aug 25, 2020 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
| M(M-115) | Apr 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
VICTOZA family patents
156. Viekira Pak (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629841 | ABBVIE | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(9 years from now) | |
| US10201542 | ABBVIE | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Dosing Schedule(D-163) | Apr 22, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using dasabuvir
Dosage: TABLET;ORAL
VIEKIRA PAK (COPACKAGED) family patents
157. Vijoice patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| Orphan Drug Exclusivity(ODE-396) | Apr 05, 2029 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 05 April, 2022
Treatment: NA
Dosage: TABLET;ORAL
VIJOICE family patents
158. Vivjoa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11247981 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | Apr 26, 2032 |
Drugs and Companies using OTESECONAZOLE ingredient
NCE-1 date: 27 April, 2031
Market Authorisation Date: 26 April, 2022
Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential
Dosage: CAPSULE;ORAL
VIVJOA family patents
159. Vivlodex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9526734 | ICEUTICA OPERATIONS | Formulation of meloxicam |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2018 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 22 October, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
VIVLODEX family patents
160. Vosevi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
|
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: NA
Dosage: TABLET;ORAL
VOSEVI family patents
161. Vumerity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8669281 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) | |
| US10080733 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9090558 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) | |
Drugs and Companies using DIROXIMEL FUMARATE ingredient
Market Authorisation Date: 29 October, 2019
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
VUMERITY family patents
162. Vyleesi (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9352013 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(9 years from now) | |
| US10286034 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(9 years from now) | |
| US9700592 | PALATIN TECHNOLOGIES | Uses of bremelanotide in therapy for female sexual dysfunction |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 21, 2024 |
Drugs and Companies using BREMELANOTIDE ACETATE ingredient
NCE-1 date: 22 June, 2023
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of hypoactive sexual desire disorder (hsdd)
Dosage: SOLUTION;SUBCUTANEOUS
VYLEESI (AUTOINJECTOR) family patents
163. Wegovy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9764003 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 04, 2024 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management according to a dose escalation schedule
Dosage: SOLUTION;SUBCUTANEOUS
WEGOVY family patents
164. Xacduro (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9309245 | ENTASIS THERAP | Beta-lactamase inhibitor compounds |
Apr, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9623014 | ENTASIS THERAP | β-lactamase inhibitor compounds |
Apr, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | May 23, 2033 |
Drugs and Companies using DURLOBACTAM SODIUM; DURLOBACTAM SODIUM; SULBACTAM SODIUM ingredient
NCE-1 date: 23 May, 2032
Market Authorisation Date: 23 May, 2023
Treatment: Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp)
Dosage: POWDER;INTRAVENOUS
XACDURO (COPACKAGED) family patents
165. Xaracoll patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11746141 | INNOCOLL PHARMS | Modified collagen |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 28, 2023 |
Drugs and Companies using BUPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 August, 2020
Treatment: NA
Dosage: IMPLANT;IMPLANTATION
XARACOLL family patents
166. Xatmep patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11116724 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US10610485 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US9855215 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US10231927 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| US9259427 | AZURITY | Methotrexate composition |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-137) | Apr 25, 2024 |
| Orphan Drug Exclusivity(ODE-138) | Apr 25, 2024 |
| Orphan Drug Exclusivity(ODE) | Apr 25, 2024 |
Drugs and Companies using METHOTREXATE SODIUM ingredient
Market Authorisation Date: 25 April, 2017
Treatment: A method for treating acute lymphoblastic leukemia; Treatment of juvenile rheumatoid arthritis
Dosage: SOLUTION;ORAL
XATMEP family patents
167. Xelstrym patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9456993 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(9 years from now) | |
| US9474722 | NOVEN PHARMS INC | Compositions and methods for transdermal delivery of amphetamine |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2025 |
Drugs and Companies using DEXTROAMPHETAMINE ingredient
Market Authorisation Date: 22 March, 2022
Treatment: A method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine
Dosage: SYSTEM;TRANSDERMAL
XELSTRYM family patents
168. Xhance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033696 | OPTINOSE US INC | Nasal delivery devices |
May, 2033
(9 years from now) | |
| US10179216 | OPTINOSE US INC | Nasal delivery devices |
Jul, 2033
(9 years from now) | |
| US10478574 | OPTINOSE US INC | Nasal administration |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway
Dosage: SPRAY, METERED;NASAL
XHANCE family patents
169. Xiidra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9085553 | NOVARTIS | LFA-1 inhibitor and methods of preparation and polymorph thereof |
Jul, 2033
(9 years from now) | |
| US11058677 | NOVARTIS | LFA-1 inhibitor formulations |
Dec, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
XIIDRA family patents
170. Xipere patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636332 | BAUSCH AND LOMB INC | Methods and devices for the treatment of ocular diseases in human subjects |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2024 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 22 October, 2021
Treatment: Treatment of macular edema associated with uveitis
Dosage: SUSPENSION;INJECTION
XIPERE family patents
171. Xphozah patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 17 October, 2023
Treatment: NA
Dosage: TABLET;ORAL
XPHOZAH family patents
172. Xpovio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8999996 | KARYOPHARM THERAPS | Hydrazide containing nuclear transport modulators and uses thereof |
Jul, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Jul 03, 2026 |
| Orphan Drug Exclusivity(ODE-257) | Jul 03, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2024 |
| Orphan Drug Exclusivity(ODE-310) | Jun 22, 2027 |
| Orphan Drug Exclusivity(ODE-346) | Dec 18, 2027 |
| New Indication(I-837) | Jun 22, 2023 |
Drugs and Companies using SELINEXOR ingredient
NCE-1 date: 04 July, 2023
Market Authorisation Date: 03 July, 2019
Treatment: NA
Dosage: TABLET;ORAL
XPOVIO family patents
173. Xtandi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11839689 | ASTELLAS | Formulations of enzalutamide |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-926) | Nov 17, 2026 |
| New Indication(I-808) | Dec 16, 2022 |
| New Indication(I-786) | Jul 13, 2021 |
Drugs and Companies using ENZALUTAMIDE ingredient
Market Authorisation Date: 04 August, 2020
Treatment: NA
Dosage: TABLET;ORAL
XTANDI family patents
174. Xtoro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9504691 | FONSECA BIOSCIENCES | Finafloxacin suspension compositions |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 17, 2019 |
| Pediatric Exclusivity(PED) | Jun 17, 2020 |
Drugs and Companies using FINAFLOXACIN ingredient
NCE-1 date: 18 June, 2019
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS;OTIC
XTORO family patents
175. Xyosted (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10821072 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Jun, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2021 |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Method of administering testosterone enanthate subcutaneously
Dosage: SOLUTION;SUBCUTANEOUS
XYOSTED (AUTOINJECTOR) family patents
176. Xyrem patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9486426 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US8772306 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US9050302 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US10213400 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US11253494 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US10864181 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
|
US9050302 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US9486426 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US8772306 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10864181 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10213400 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US11253494 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-231) | Oct 26, 2025 |
| Pediatric Exclusivity(PED) | Apr 26, 2026 |
| New Patient Population(NPP) | Oct 26, 2021 |
| Orphan Drug Exclusivity(ODE) | Nov 18, 2012 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 17 July, 2002
Treatment: Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.; Method of reducing adverse effects in...
Dosage: SOLUTION;ORAL
XYREM family patents
177. Xywav patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9132107 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US8901173 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US10675258 | JAZZ | Method of using gamma-hydroxybutyrate compositions for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US10195168 | JAZZ | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US8591922 | JAZZ | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US11554102 | JAZZ | Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders |
Jan, 2033
(8 years from now) | |
| US8772306 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US10213400 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US9486426 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US11253494 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US10864181 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US9050302 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
|
US9050302 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US11253494 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10864181 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US8772306 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US9486426 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
|
US10213400 (Pediatric) | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-361) | Jul 21, 2027 |
| New Indication(I-870) | Aug 12, 2024 |
| Orphan Drug Exclusivity(ODE-369) | Aug 12, 2028 |
| Orphan Drug Exclusivity(ODE-231) | Jul 21, 2027 |
| New Product(NP) | Jul 21, 2023 |
Market Authorisation Date: 21 July, 2020
Treatment: Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb; Method of tr...
Dosage: SOLUTION;ORAL
XYWAV family patents
178. Yosprala patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9987231 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Jan, 2033
(8 years from now) | |
| US9539214 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 14, 2019 |
Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient
Market Authorisation Date: 14 September, 2016
Treatment: For secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin-associated gastric ulcers; Treatment or secondary prevention of cardiovascular disease, ...
Dosage: TABLET, DELAYED RELEASE;ORAL
YOSPRALA family patents
179. Zerviate patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9254286 (Pediatric) | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 30, 2020 |
| Pediatric Exclusivity(PED) | Nov 30, 2020 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2017
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
ZERVIATE family patents
180. Zohydro Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421200 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9433619 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10456393 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10722511 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9339499 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9326982 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9610286 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9333201 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10028946 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10322120 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9265760 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 25, 2016 |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 25 October, 2013
Treatment: Treatment of pain in patients with hepatic impairment
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ZOHYDRO ER family patents
181. Zulresso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10322139 | SAGE THERAP | Neuroactive steroid formulations and methods of treating CNS disorders |
Jan, 2033
(8 years from now) | |
| US10251894 | SAGE THERAP | Anticonvulsant activity of steroids |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| New Patient Population(NPP) | Jun 16, 2025 |
Drugs and Companies using BREXANOLONE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: Method of treating postpartum depression
Dosage: SOLUTION;INTRAVENOUS
ZULRESSO family patents
182. Zydelig patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8865730 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(8 years from now) | |
| US10730879 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(8 years from now) | |
| US9469643 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 23, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2019 |
| Orphan Drug Exclusivity(ODE-70) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-71) | Jul 23, 2021 |
Drugs and Companies using IDELALISIB ingredient
NCE-1 date: 23 July, 2018
Market Authorisation Date: 23 July, 2014
Treatment: For the treatment of patients with cll, fl, or sll
Dosage: TABLET;ORAL
ZYDELIG family patents
List of large molecules
1. List of Humira large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9085618 | ABBVIE INC. | Low acidic species compositions and methods for producing and using the same |
Mar, 2033
(8 years from now) | |
| US9334319 | ABBVIE INC. | Low acidic species compositions |
Mar, 2033
(8 years from now) | |
| US9290568 | ABBVIE INC. | Methods to control protein heterogeneity |
Mar, 2033
(8 years from now) | |
| US9708400 | ABBVIE INC. | Methods to modulate lysine variant distribution |
Mar, 2033
(8 years from now) | |
| US9181572 | ABBVIE INC. | Methods to modulate lysine variant distribution |
Mar, 2033
(8 years from now) | |
| US9181337 | ABBVIE INC. | Modulated lysine variant species compositions and methods for producing and using the same |
Mar, 2033
(8 years from now) | |
| US9499616 | ABBVIE INC. | Modulated lysine variant species compositions and methods for producing and using the same |
Mar, 2033
(8 years from now) | |
| US9359434 | ABBVIE INC. | Cell culture methods to reduce acidic species |
Mar, 2033
(8 years from now) | |
| US9346879 | ABBVIE INC. | Protein purification methods to reduce acidic species |
Mar, 2033
(8 years from now) | |
| US9315574 | ABBVIE INC. | Low acidic species compositions and methods for producing and using the same |
Apr, 2033
(8 years from now) | |
| US9150645 | ABBVIE INC. | Cell culture methods to reduce acidic species |
May, 2033
(9 years from now) | |
| US9266949 | ABBVIE INC. | Low acidic species compositions and methods for producing and using the same |
May, 2033
(9 years from now) |
Ingredients: ADALIMUMAB
2. List of Evenity large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8017120 | NA | Method for inhibiting bone resorption |
Apr, 2033
(8 years from now) |
Ingredients: ROMOSOZUMAB-AQQG
3. List of Tysabri large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9562252 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
May, 2033
(9 years from now) |
Ingredients: NATALIZUMAB
4. List of Lucentis large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10421984 | GENENTECH, INC. | Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele |
Sep, 2033
(9 years from now) |
Ingredients: RANIBIZUMAB
5. List of Emgality large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9073991 | NA | NA |
Sep, 2033
(9 years from now) |
Ingredients: GALCANEZUMAB
6. List of Avastin large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10906934 | GENENTECH, INC. | Protein purification methods |
Oct, 2033
(9 years from now) |
Ingredients: BEVACIZUMAB